Catalent's Clinical Trial Supply Facility in Shanghai, China Opens for Business
Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, has announced that construction and validation of its Clinical Supply facility in Shanghai, China has been completed. Catalent business leaders, local employees, customers and partners celebrated at a site opening ceremony on 8 November 2013, less than 9 months after construction began on the site.
It is the first clinical supply facility in China to provide end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution. The facility is also validated to support biologics requiring refrigerated and frozen supply chain management. Catalent has already secured customer projects for the site, which is now undergoing customer validation for the supply of clinical trial materials.
Catalent currently supports the clinical trial supply needs of the top 25 pharmaceutical companies and more than 300 small innovators from all over the world. The new, state-of-the-art, 31,000 sq ft facility has been constructed to the company’s proven ‘center of excellence’ guidelines and will operate to Catalent’s global Quality Management System. The Catalent (Shanghai) Clinical Trial Supplies Co., Ltd facility is the eighth in Catalent’s global clinical supply network and is located in Shanghai’s Waigaoqiao Free Trade Zone.
“China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” commented Scott Houlton, President of Development and Clinical Services at Catalent. “Having started work on our China clinical supply strategy 2 years ago, I’m excited to see this strategy implemented and the new site open for business. It is a great addition to Catalent’s global clinical supply network and will help to better serve our customers increasing need for clinical trials in Asia.”
Dr Weiyan “Jackson” Zhu, Catalent's Country General Manager for China added: “The recently appointed local management team brings a huge combined prior experience of clinical trials management, pharmaceuticals and healthcare. Together with Catalent’s GMP facility in Singapore, the company is well positioned to serve the clinical trials needs of our regional and global customers.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance